key: cord-0775355-mr8n09lf
authors: Ramon, André; Greigert, Hélène; Ornetti, Paul; Bonnotte, Bernard; Samson, Maxime
title: Mimickers of Large Vessel Giant Cell Arteritis
date: 2022-01-19
journal: J Clin Med
DOI: 10.3390/jcm11030495
sha: 67909b694ba57f0a74b29e20b6b3baf5826d7cf0
doc_id: 775355
cord_uid: mr8n09lf

Giant cell arteritis (GCA) is a large-vessel granulomatous vasculitis occurring in patients over 50-year-old. Diagnosis can be challenging because there is no specific biological test or other diagnoses to consider. Two main phenotypes of GCA are distinguished and can be associated. First, cranial GCA, whose diagnosis is usually confirmed by the evidence of a non-necrotizing granulomatous panarteritis on temporal artery biopsy. Second, large-vessel GCA, whose related symptoms are less specific (fever, asthenia, and weight loss) and for which other diagnoses must be implemented if there is neither cephalic GCA nor associated polymyalgia rheumatica (PMR) features chronic infection (tuberculosis, Coxiella burnetti), IgG4-related disease, Erdheim Chester disease, and other primary vasculitis (Behçet disease, relapsing polychondritis, or VEXAS syndrome). Herein, we propose a review of the main differential diagnoses to be considered regarding large vessel vasculitis.

Giant cell arteritis (GCA) is the most common vasculitis in patients >50 years. It is a granulomatous vasculitis that affects large vessels (i.e., arteries outside the organs) [1] , particularly the aorta and its extracranial branches (carotid, subclavian, axillary, vertebral, maxillary, occipital, and temporal arteries) [2] .

Two phenotypes of GCA can be distinguished: 1-cranial GCA" that was first described by Bayard Horton in 1932 [3] , with temporal headaches, jaw claudication, and scalp tenderness exposing patients to cranial ischemic manifestations (stroke, acute anterior ischemic optic neuropathy, occlusion of the central retinal artery). 2-"Large vessel (LV)-GCA" phenotype, which accounts for 30-70% of GCA patients. These two phenotypes can be associated, but some patients may have isolated involvement of the large arteries without cranial involvement. In this case, the diagnosis of GCA is more difficult [4] because symptoms are usually nonspecific and because other diagnoses have to be considered. Furthemore, these patients have an increased risk of aortic complications and/or cardiovascular events during the follow-up [5, 6] . The risk of relapse also appears to be greater in this population, thus their identification is crucial [7] .

The main manifestations of LV-GCA are constitutional symptoms (asthenia, anorexia, weight loss, unexplained fever) and nonspecific increase in acute phase reactants (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP] ). Signs of vascular insufficiency (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP] ). Signs of vascular insufficiency are more common in LV-GCA than in cranial-GCA, such as asymmetric blood pressure, abolition of peripheral pulses, limb claudication, and/or ischemia [8] .

Currently, no specific diagnostic test is available to confirm LV-GCA since biopsy of these arteries is usually not performed in routine clinical practice except in the case of surgical intervention. LV-GCA is usually suspected by indirect evidence of large vessel vasculitis on vascular imaging such as an angio-CT scan, 18 FDG PET, or angio-MRI. Aorta is the main site of inflammation, followed by the carotid and subclavian arteries [9] (Figure 1, panel A) . Diagnostic of LV-GCA is highly suggested when large vessel vasculitis is associated with clinical or imaging PMR features [10] . Because of the lack of specificity of the initial clinical features and the absence of diagnostic tests for many conditions that can lead to inflammatory large vessel involvement (LV-GCA-like) (Table 1) , the diagnosis of LV-GCA can be challenging and require that clinicians be very familiar with the differential diagnoses to be evoked. Because of the lack of specificity of the initial clinical features and the absence of diagnostic tests for many conditions that can lead to inflammatory large vessel involvement (LV-GCA-like) (Table 1) , the diagnosis of LV-GCA can be challenging and require that clinicians be very familiar with the differential diagnoses to be evoked.

In this review, the main differential diagnoses of LV-GCA are discussed. Syphilis is a rare cause of aortitis. Most patients are asymptomatic, with an average age of 60 years at diagnosis [11] . It usually appears after 20 years of disease progression, in its tertiary phase [12] . In a series of 23 syphilitic patients, Roberts et al. [13, 14] reported aneurysms in the ascending aorta (100%), the aortic arch (52%), and the descending thoracic aorta (43%). No involvement of the abdominal aorta was found. It is hypothesized that the absence of vasa vasorum in the abdominal aorta may explain the specific tropism of syphilis for the thoracic aorta [13] . In all cases, the aneurysm was fusiform. Histological analysis revealed thickening of the intima and the adventitia with an infiltrate of mononuclear cells and thickening/obliteration of the vasa vasorum. Media was not thickened but replaced by fibrous tissue with some mononuclear elements. Treatment relies on penicillin and surgical aneurysm resection as appropriate.

Tuberculous aortitis is a rare condition. Aortic involvement is suspected in the presence of limb claudication, asymmetric blood pressure, and/or a decrease in peripheral pulses associated with pulmonary signs (nodular opacity, mediastinal adenopathy, pleural effusion) [15] or nonspecific signs such as an altered general condition, night sweats, and fever. The abdominal aorta is the most frequently involved (66% of cases) [12] .

The classical features are pseudoaneurysms resulting from the hematogenous spread of Mycobacterium tuberculosis or damage to the vessel wall by contiguous adenitis. The evolution is generally favorable after anti-tuberculosis treatment, generally lasting for 12 to 18 months.

Coxiella burnetti can cause aortitis. Some cases of Q fever mimicking LV-GCA have been reported [16] [17] [18] . In a retrospective French multicenter study, 8/55 aortitis revealed Coxiella burnetti infection. Main aortitis localization was abdominal (54%) and thoracic (33%). Fusiform aneurysm was the main aortitis pattern [19] . The diagnosis is difficult because the positive serology may be related to an old infection, unrelated to the aortic involvement. The study of antibody avidity can help date the infection. A low avidity indicates a recent infection. The diagnosis of certainty is provided by demonstrating the bacterium by culture, PCR, or immunohistochemistry on vascular or prosthetic tissue or a periarterial abscess or spondylodiscitis in case of contiguous involvement near the aorta. Treatments rely on a combination of hydroxychloroquine (600 mg once a day) and doxycycline (100 mg twice a day) for 24 months.

Many bacterial germs can cause aortitis. The most common are gram-positive cocci, Staphylococcus aureus, and Streptococcus, the latter often being implicated in the occurrence of aortic aneurysm in the context of infectious endocarditis [20] [21] [22] . Cases of Salmonella aortitis have also been reported, mainly in the abdominal aorta [23, 24] .

Other germs have been reported to trigger aortitis: Listeria monocytogenes [25] , Pasteurella multicoda [26] , and Clostridium septicum [27] .

The diagnosis is usually suspected based on the clinical presentation, the patient's medical history (immunosuppression), and the circumstances of occurrence (bite). Gramnegative bacillus involvement may reveal associated malignancy [28] .

During the COVID-19 pandemic, Lecler et al. reported a 70% increase in GCA cases at their center, raising the question of a direct role of SARS-CoV-2 in the occurrence of GCA [29] .

Cases of aortitis attributed to SARS-CoV-2 have also been reported [30, 31] . Silvestri [11.7%] ). Main clinic-biological features were fever (47%), chest pain (47%), respiratory symptoms (35.2%), and lymphopenia (17.6%). Aortic pathology included: type A aortic dissection (64.7%), new pathology of previous aortic graft (11.7%), aortitis (11.7%), thoracoabdominal aortic aneurysm (5.9%), one ruptured aortic aneurysm (5.9%), and one aortic embolizing thrombosis (5.9%). Open surgery or endovascular treatment were carried out in 58.8 and 17.6% of cases, respectively. Four patients (23.5%) died, three before surgery.

SARS-CoV-2-induced aortitis is thought to be an infectious aortitis occurring during the viremic phase. During this phase, the virions would directly attack the vascular endothelium, which highly expressed angiotensin-converting enzyme-2 receptors, leading to arterial inflammatory lesions [32] . Large vessel involvement during SARS-CoV-2 infection could be due to a direct effect of the virus on the endothelium leading to endothelial dysfunction and recruitment of inflammatory cells. Manenti et al. [33] hypothesized that atherosclerosis and, more particularly, the presence of ulcerated plaques, which is common in elderly subjects, could be a facilitating factor. However, there are currently too few cases to accurately study the pathogenesis of these vasculitis.

Some cases of GCA following SARS-CoV-2 vaccination have also been described. Using VigiBase analysis (26, 246 Sauret et al. [35] also reported the case of a patient who developed GCA following SARS-CoV-2 vaccination. The patient was positive for HLA-DR4, which made the author hypothesize that HLA could play a role in the occurrence of post-vaccinal GCA.

IgG4-RD is a fibro-inflammatory condition characterized by an IgG4-rich lymphoplasmacytic infiltrate. It is a multi-systemic disease involving the biliary tree, salivary glands, lungs, periorbital tissues, kidneys, meninges, prostate, pericardium, skin, retroperitoneum, and aorta [36] . Lymph nodes enlargement is reported in 14% of IgG4-RD patients [37] ( Figure 1, panel B) The diagnosis is suspected in cases of elevated serum IgG4 level (>1.35 g/L). However, isolated elevated serum IgG4 can be observed in pancreatic cancer and the normal population [38] . Thus, histopathological analysis is the cornerstone of the diagnosis. The most specific histological lesions are a lympho-plasmacytic infiltrate associated with storiform fibrosis, obliterating thrombosis, and a small to moderate eosinophilic infiltrate [39] . Even if the IgG4 infiltrate is not specific to the disease, an IgG4 bearing plasma cell to IgG bearing plasma cell ratio >50% in affected tissues is very suggestive for diagnosing IgG4-RD [36] .

Aortic involvement is variable in IgG4-RD (10-50% of cases) [40, 41] . It is characterized by peri-aortitis (20 to 36%) that more frequently affects the sub-renal aorta and aortitis ( Figure 1 , panel C) (8%) that more frequently affects the thoracic aorta and leads to the occurrence of inflammatory aneurysms. Retroperitoneal fibrosis is found in 3 to 19% of patients and can cause obstructive renal failure. Isolated aortic involvement is rare because 80% of patients have associated symptoms of IgG4-RD [42] .

Acute phase reactants are usually moderately increased. From 89 IgG4-RD with large vessels vasculitis, Peng et al. reported a mean ESR value of 44 mm/h (18-75) and mean usCRP of 6.72 mg/L (2.14-24.65) [43] Wallace et al. [44] identified 4 patient phenotypes: pancreato-hepatobiliary, head and neck, aortitis/retroperitoneal fibrosis, and Mikulicz disease. The treatment of IgG4-RD relies on systemic glucocorticoids. The disease is very sensitive to glucocorticoids but tends to relapse when the doses are decreased. Rituximab is, therefore, very useful in this indication [45] .

Aortic involvement in BD occurs in 4-34% of cases [46, 47] . The most frequent lesions are aneurysms (70%) of the abdominal (11%) and thoracic (5%) aorta. Diffuse aortitis is rarer (3%) [46] .

Suggestive features of the disease are mainly mouth and genital ulcers (63 to 100%), skin involvement (68%), ophthalmological disorders (48%), and joint manifestations (38%) [46] .

Features associated with aortic involvement include abdominal or lumbar pain, limb claudication, and aortic insufficiency. Fever is present in 11% of cases. [48] . Arterial involvement management relies on glucocorticoids or other immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporine A). Monoclonal anti-TNF antibodies can be considered in refractory cases. In the case of artery aneurysms, cyclophosphamide and corticosteroids are required before surgical intervention or stenting [49, 50] .

Survival rates for patients with aortic involvement are significantly lower than patients without aortic involvement [46] .

ECD is a histiocytosis of the "L" group [51] characterized by the presence of foamy histiocytes CD68 + CD163 + FXIIa + CD1a − . More than 80% of patients have an activating mutation of the MAPK (Mitogen-Activated Protein Kinase) pathway, mainly BRAF V600E (57% to 70%) [52] .

ECD predominantly affects adult males with a median age of 55 years at diagnosis. The usual features of this multi-systemic disease include cardiac involvement (right atrium pseudotumor, coronary infiltration, pericarditis), xanthelasma, long bone osteosclerosis (Figure 2, panel A) , diabetes insipidus, central nervous system involvement, renal involvement (hairy kidneys) (Figure 2, panel B) , retroperitoneal fibrosis, pulmonary involvement (interstitial lung disease, pleural infiltration) [53] .

Aortic involvement is reported in 40% to 60% of cases [52, 54] , in the form of a periaortic infiltrate (coated aorta) (Figure 2, panel C,D) or ectasia affecting the thoracic and abdominal aorta, which may extend to the main branches of the aorta. It rarely affects the pelvic and lower limb arteries. This aortitis is usually asymptomatic. Treatment relies on pegylated interferon-α (IFN-α) as first line therapy. Second line therapies include BRAF inhibitors (vemurafenib) or MEK inhibitors (cobimetinib) according to mutation profile [53] .

Few cases of GCA secondary to the introduction of ICI (anti PD-1/PD-L1, anti CTLA-4) therapy have been reported even though PD-1/PD-L1 pathway dysfunction has been demonstrated during GCA [55] .

Among the few cases reported [56, 57] , patients were mostly treated with anti PD-1 antibodies for metastatic melanoma. Ophthalmologic signs and PMR were mentioned in two and one case, respectively.

In a retrospective study assessing cardiovascular toxicity of ICI, authors reported 18 cases of temporal GCA, with a clear male predominance (94.5%) and a mean age at diagnosis of 77.8 years. More than half of the cases occurred following an anti CTLA-4 ICI (55%). Only 16.7% of patients had headaches, and 27% had visual signs [58] .

G-CSF is a human granulocyte hematopoietic growth factor. Recombinant G-CSF is used as a primary or secondary prophylaxis to reduce the risk of neutropenia secondary to myelosuppressive cytotoxic chemotherapy [59] . There are several reports of aortitis in patients treated with recombinant G-CSF [60] [61] [62] . Oshima et al. [63] , based on 3409 patients treated with recombinant G-CSF, reported a significant association between aortitis and the use of G-CSF (odds ratio [OR] = 45.87; p < 0.001).

(57% to 70%) [52] .

ECD predominantly affects adult males with a median age of 55 years at diagnosis. The usual features of this multi-systemic disease include cardiac involvement (right atrium pseudotumor, coronary infiltration, pericarditis), xanthelasma, long bone osteosclerosis (Figure 2, panel A) , diabetes insipidus, central nervous system involvement, renal involvement (hairy kidneys) (Figure 2, panel B) , retroperitoneal fibrosis, pulmonary involvement (interstitial lung disease, pleural infiltration) [53] . In most cases, patients have recovered within 1 month after systemic glucocorticoid therapy and discontinuation of G-CSF [60] [61] [62] .

A few cases of aortitis have been reported in rheumatoid arthritis. Factors associated with aortitis include severe arthritis, duration of disease >1 year, the presence of erosions, and rheumatoid nodules. The presence of HLA-DRB1*0401 has been reported in the old series as associated with the occurrence of rheumatoid vasculitis [64] .

Aortitis has also been reported in spondyloarthritis (ankylosing spondylitis and psoriatic arthritis) [65] . Involvement of the ascending aorta and the aortic arch is the most common; involvement of the abdominal aorta is rarer [66] .

Aortic involvement has also been reported in relapsing polychondritis (RP) [67] [68] [69] [70] . Involvement of the ascending aorta and the aortic arch is the most common. Le Besnerais et al. [70] reported aortic involvement in 11/172 patients with RP (aortitis [18%], isolated aneurysm [36%], aortitis + aneurysm [18%]). The mean time to diagnose aortic involvement was 27 months after the diagnosis of RP. More than half of the patients were male, had fever and asthenia. Aortic involvement is associated with a high mortality rate in this population (23-27%) .

Some cases of large vessel involvement have been reported in sarcoidosis. The diagnosis can be very challenging in the case of sarcoidosis, especially since sarcoidosis can result in rheumatologic involvement such as PMR [71] . Histological analysis of affected tissues, vascular or not, shows the presence of giganto-cellular granulomas without necrosis. Treatment relies on systemic glucocorticoid therapy [72] .

Similarly, cases of aortitis have been reported in systemic lupus erythematosus (SLE) [73] . At diagnosis, clinical signs are nonspecific (fever, dyspnea, and chest pain), and inflammatory markers (CRP and ESR) are elevated. Aortitis mainly affected the ascending aorta with circumferential thickening (60%) or inflammatory aneurysm (20%). Most of the patients had isolated aortitis without another clinical sign of SLE. All patients showed a high titer of anti-nuclear antibodies with anti-double-stranded DNA and/or anti smith antibodies.

A new disease based on clonal hematopoiesis, named VEXAS (Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), has been identified recently [74] . VEXAS syndrome is related to somatic mutations in the UBA1 gene occurring in myeloid cells. The frequency of this disease is probably underestimated, and its precise clinical features are largely unknown. Patients are men with recurrent fever, dermatologic manifestations (neutrophilic dermatoses and cutaneous vasculitis), pulmonary infiltrate, ear and nose chondritis, macrocytic anemia, and hematopoietic dyspoiesis. Some patients also have large vessel vasculitis. The disease is sensitive to high-dose glucocorticoids, but patients are generally dependent on high doses and therefore quickly require the use of other therapies, including tocilizumab, 5-azacitidine, or ruxolitinib [75, 76] . VEXAS syndrome should be discussed in male patients with atypical features of LV-GCA together with hematologic abnormalities (macrocytic anemia or myelodysplastic syndrome), high-dose corticodependence, and/or overlapping with RP or neutrophilic dermatoses [77] .

Atherosclerosis may raise suspicion of LV-GCA, but some characteristics usually differentiate these two conditions. CRP is usually not significantly elevated (i.e., <10 mg/L) in atherosclerosis, by contrast with LV-GCA [78, 79] . The topography of the lesions can also guide the clinician. Atheromatous lesions are most often located in the vessels of the lower limbs and form focal lesions at the origin of the collaterals. By contrast, GCA lesions are diffuse and more commonly involve the ascending aorta, supra-aortic trunks, and the aortic arch [80] .

When performing 18 FDG PET, the intensity of FDG tracer uptake helps in distinguishing these two diagnoses. The uptake is generally lower in atherosclerosis (grade 1) than in GCA (grade 2 or 3). In addition, atherosclerosis lesions have a more heterogeneous and irregular appearance, whereas LV-GCA lesions are more homogeneous and linear [81, 82] .

Features of LV-GCA (weight loss, asthenia, anorexia, fever, biological inflammatory syndrome) may raise suspicion of malignancy.

According to some studies, associations between GCA and malignancy are reported in 10-25% of patients [83, 84] with a relative risk (RR) of 2.16 within 6 months after the diagnosis of GCA [85] . A retrospective study reported a higher risk of solid malignancy (Hazard Ratio (HR) = 1.2) and hematological malignancy in GCA compared to a control population. Higher age at diagnosis and male gender were associated with malignancy [86] . By contrast, other studies did not confirm these results [87] .

Beyond this possible association between GCA and malignancy, some cases of paraneoplastic GCA are reported [88] , notably during myelodysplastic syndrome [89, 90] , but these cases have been reported before the first description of VEXAS syndrome.

PMR is an inflammatory disorder with severe pain and stiffness of the scapular and pelvic girdle occurring in patients over 50 years associated with increased acute phase reactants (ESR, CRP) [10] . It is associated with GCA in 16 to 21% of cases, and 40 to 60% of patients with GCA have associated features of PMR [91] . The presence of PMR is therefore a feature that is often very suggestive of GCA in case of large vessel vasculitis without cranial signs of GCA.

However, inflammatory girdle pain may indicate other and sometimes more severe conditions that warrant specific diagnostic and therapeutic management. Many diseases can mimic PMR (PMR-like) and need to be ruled out before confirming the diagnosis of PMR, especially as some may be accompanied by large vessel vasculitis as elderly onset rheumatoid arthritis (EORA) and spondyloarthritis.

EORA can mimic PMR by involving the large proximal joints, usually with a sudden onset, associated with general signs and a male predominance [92] . A key difference between EORA and PMR is the presence of the rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in EORA. Moreover, Pease et al. reported that RF-negative EORA was more frequently associated with peripheral small joint involvement (metacarpophalangeal and proximal interphalangeal joint) (80% vs. 23% in PMR). Similarly, in a small series of patients (15 PMR and 7 EORA), Wakura et al. [93] demonstrated, using 18 FDG PET of 9 anatomical sites, that PMR patients had more frequent fixation abnormalities than EORA subjects. The main differences between the two groups were periarticular hyperfixation of the shoulder girdle, the coxofemoral joint, the pectineal muscle, and the ischial tuberosity entheses, as well as hyperfixation of the spinous processes in the cervical and lumbar regions and posterior joint involvement in the lumbar region in favor of the PMR group.

Late-onset spondyloarthritis (LOPS) may involve the cervical spine and shoulder girdle with constitutional manifestations as low-grade fever, asthenia, and weight loss in association with increased acute phase reactants [94] . Radiographic sacroiliitis and HLA-B27 positivity are key elements for diagnosis.

Isolated LV-GCA remains a diagnostic challenge for the clinician, as many conditions may be responsible for large vessel involvement. Its early diagnosis is important because of the risk of arterial complications in the medium and long term that can compromise a patient's survival. The diagnosis is based on the association of clinical (associated PMR symptoms) and biological and imaging features and requires ruling various conditions, particularly infectious and other inflammatory diseases.

In the absence of specific disease markers, the clinician must be aware of the numerous differential diagnoses to offer patients early and appropriate management. 

Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Giant-Cell Arteritis and Polymyalgia Rheumatica

An Undescribed Form of Arteritis of Temporal Vessels

The Spectrum of Giant Cell Arteritis and Polymyalgia Rheumatica: Revisiting the Concept of the Disease

Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup

Large-Vessel Involvement and Aortic Dilation in Giant-Cell Arteritis. A Multicenter Study of 549 Patients

Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis

Large-Vessel Giant Cell Arteritis: Diagnosis, Monitoring and Management

Large-Vessel Involvement in Giant Cell Arteritis: A Population-Based Cohort Study of the Incidence-Trends and Prognosis

Giant Cell Arteritis and Polymyalgia Rheumatica: Current Challenges and Opportunities

Thoracic infectious aortitis: Microbiology, pathophysiology and treatment

Syphilis as a Cause of Thoracic Aortic Aneurysm

Aortitis: Still a Current Common Cause of Aneurysm of the Tubular Portion of Ascending Aorta

A Case of Giant Cell Arteritis Associated with Culture-Proven Coxiella Burnetii Aortitis

Clinical Features and Complications of Coxiella Burnetii Infections From the French National Reference Center for Q Fever

Systemic Immune Presentations of Coxiella Burnetii Infection (Q Fever)

Infectious Thoracic Aortitis: A Literature Review

Infectious Aortitis Due to Penicillin-Resistant Streptococcus Pneumoniae

Case of Ruptured Staphylococcus Aureus Aortitis: Presentation and Management

The Spectrum of Cardiovascular Infections Due to Salmonella Enterica: A Review of Clinical Features and Factors Determining Outcome

Surgical Pathology of Infected Aneurysms of the Descending Thoracic and Abdominal Aorta: Clinicopathologic Correlations in 29 Cases (1976 to 1999)

Suspected Giant Cell Aortitis: From Multiple Aortic Structural Damage to Fatal Listeria Sepsis, a Case Report

Deadly Case of Pasteurella Multocida Aortitis and Mycotic Aneurysm Following a Cat Bite

Clostridium Septicum Aortitis: Report of Two Cases and Review of the Literature

Clostridium Septicum Aortitis and Cecal Adenocarcinoma. Case Rep

Increased Rather than Decreased Incidence of Giant-Cell Arteritis during the COVID-19 Pandemic

Florid Aortitis Following SARS-CoV-2 Infection

Aortic Pathology During COVID-19 Pandemics. Clinical Reports in Literature and Open Questions on the Two Co-Occurring Conditions

Endothelial Cell Infection and Endotheliitis in COVID-19

Vasculitis and Aortitis: COVID-19 Challenging Complications

Risk of Giant Cell Arteritis and Polymyalgia Rheumatica Following COVID-19 Vaccination: A Global Pharmacovigilance Study

Case of Giant Cell Arteritis After SARS-CoV-2 Vaccination: A Particular Phenotype?

IgG4-Related Disease

Serologic Issues in IgG4-Related Systemic Disease and Autoimmune Pancreatitis

IgG4-Related Disease: A Cross-Sectional Study of 114 Cases

IgG4-Related Systemic Disease Accounts for a Significant Proportion of Thoracic Lymphoplasmacytic Aortitis Cases

Inflammatory Abdominal Aortic Aneurysm: Close Relationship to IgG4-Related Periaortitis

Overview of IgG4-Related Aortitis and Periaortitis. A Decade since Their First Description

IgG4-Related Aortitis/Periaortitis and Periarteritis: A Distinct Spectrum of IgG4-Related Disease

ACR/EULAR IgG4-RD Classification Criteria Committee Clinical Phenotypes of IgG4-Related Disease: An Analysis of Two International Cross-Sectional Cohorts

Rituximab for IgG4-Related Disease: A Prospective, Open-Label Trial

Term Outcome of Arterial Lesions in Behçet Disease: A Series of 101 Patients

Pathologic Features of Behçet's Syndrome: A Review of Japanese Autopsy Registry Data

Aortic inflammatory lesions in Behçet's disease

Agents for Behçet's Disease: Analysis of Published Data on 369 Patients

Update of the EULAR Recommendations for the Management of Behçet's Syndrome

Revised Classification of Histiocytoses and Neoplasms of the Macrophage-Dendritic Cell Lineages

Erdheim-Chester Disease: A Concise Review

The Clinical Spectrum of Erdheim-Chester Disease: An Observational Cohort Study

Immunoinhibitory Checkpoint Deficiency in Medium and Large Vessel Vasculitis

Giant Cell Arteritis Manifesting as Retinal Arterial Occlusion and Paracentral Acute Middle Maculopathy in a Patient on Pembrolizumab for Metastatic Uveal Melanoma

Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab

Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients with High-Risk Stage II or Stage III/IV Breast Cancer

Granulocyte Colony-Stimulating Factors and Aortitis: A Rare Adverse Event

Aortitis: Two Cases and Review of the Literature

Pegfilgrastim-Associated Large-Vessel Vasculitis Developed during Adjuvant Chemotherapy for Breast Cancer: A Case Report and Review of the Literature

Granulocyte Colony-Stimulating Factor-Associated Aortitis in the Japanese Adverse Drug Event Report Database

Large Vessel Vasculitis and Spondyloarthritis: Coincidence or Associated Diseases?

Abdominal Aortitis in HLA-B27 + Spondyloarthritis: Case Report with 5-Year Follow-up and Literature Review

Efficacy of Tocilizumab Highlighted by FDG-PET/CT in a Patient with Relapsing Polychondritis-Associated Aortitis

Cardiovascular Involvement in Relapsing Polychondritis

Aortic Involvement in Relapsing Polychondritis: Case-Based Review

Aortic Involvement in Relapsing Polychondritis

Non-Infectious Aortitis: A Report of 32 Cases from a Single Tertiary Centre in a 4-Year Period and Literature Review

A Fatal, Inflammatory Cardiovascular Complication in Systemic Lupus Erythematosus

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease

Azacitidine for Patients with Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic Syndrome (VEXAS) and Myelodysplastic Syndrome: Data from the French VEXAS Registry

A Case of VEXAS Syndrome Associated with EBV-Associated Hemophagocytic Lymphohistiocytosis

Further Characterization of Clinical and Laboratory Features in VEXAS Syndrome: Large-Scale Analysis of a Multicentre Case Series of 116 French Patients

Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis

Prevalence of a Normal C-Reactive Protein with an Elevated Erythrocyte Sedimentation Rate in Biopsy-Proven Giant Cell Arteritis

Non-Infectious Aortitis of the Ascending Aorta: A Histological and Clinical Correlation of 71 Cases Including Overlap with Medial Degeneration and Atheroma-A Challenge for the Pathologist

Inflammation, Atherosclerosis, and Coronary Artery Disease: PET/CT for the Evaluation of Atherosclerosis and Inflammation

Role of Imaging Studies in the Diagnosis and Follow-up of Large-Vessel Vasculitis: An Update

Cancer Risk in Patients Hospitalized with Polymyalgia Rheumatica and Giant Cell Arteritis: A Follow-up Study in Sweden

Risk of Malignancy in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

The Incidence and Predictors of Solid-and Hematological Malignancies in Patients with Giant Cell Arteritis: A Large Real-World Database Study

No Increased Frequency of Malignant Neoplasms in Polymyalgia Rheumatica and Temporal Arteritis. A Prospective Longitudinal Study of 398 Cases and Matched Population Controls

Vilardell-Tarres, M. Paraneoplastic Vasculitis in Patients with Solid Tumors: Report of 15 Cases

Simultaneous Presentation of Giant Cell Arteritis and Myelodysplastic Syndrome in an Elderly Japanese Man

Paraneoplastic Large-Vessel Vasculitis Associated with Myelodysplastic Syndrome

Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review

Elderly-Onset Rheumatoid Arthritis. Rheum Dis

Differentiation between Polymyalgia Rheumatica (PMR) and Elderly-Onset Rheumatoid Arthritis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Is Enthesitis a New Pathological Lesion in PMR?

Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations